Vigil Neuroscience (VIGL)
(Delayed Data from NSDQ)
$3.25 USD
+0.01 (0.31%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $3.24 -0.01 (-0.31%) 6:00 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Vigil Neuroscience, Inc. (VIGL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.25 | $23.00 | $4.00 | 401.54% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Vigil Neuroscience, Inc. comes to $16.25. The forecasts range from a low of $4.00 to a high of $23.00. The average price target represents an increase of 401.54% from the last closing price of $3.24.
Analyst Price Targets (8 )
Broker Rating
Vigil Neuroscience, Inc. currently has an average brokerage recommendation (ABR) of 1.34 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.34 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy, representing 87.5% of all recommendations. A month ago, Strong Buy represented 87.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
6/28/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/18/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
2/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/16/2023 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.34 |
ABR (Last week) | 1.34 |
# of Recs in ABR | 8 |
Average Target Price | $16.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -0.54 |